Ocuphire Pharma, Inc. (OCUP) NASDAQ
1.17
-0.16(-12.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.17
-0.16(-12.03%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.33 |
| Day High | 1.36 |
| Day Low | 1.07 |
| 52-Week High | 3.4 |
| 52-Week Low | 1.07 |
| Volume | 675,971 |
| Average Volume | 139,151 |
| Market Cap | 31.74M |
| PE | -2.17 |
| EPS | -0.54 |
| Moving Average 50 Days | 1.27 |
| Moving Average 200 Days | 1.74 |
| Change | -0.16 |
Data not available
Ocuphire Pharma Announces Acquisition of Opus Genetics
GlobeNewswire Inc.
Oct 22, 2024 8:05 PM GMT
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal
Ocuphire Pharma Announces Acquisition of Opus Genetics
GlobeNewswire Inc.
Oct 22, 2024 8:05 PM GMT
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
GlobeNewswire Inc.
Sep 30, 2024 12:00 PM GMT
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profileFARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clin